← Patent-cliff monitor Loss of exclusivity September 2032 latest FDA-listed patent expiry
Company TAKEDA PHARMACEUTICALS USA INC
Drug detail Brand name TRINTELLIX Active ingredient VORTIOXETINE HYDROBROMIDE Strength EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Dosage form TABLET Route ORAL Modality Small molecule FDA approval September 2013 Marketing status DISCN
Listed patents Patent Expires Type 9278096*PED September 2032 — 9278096 March 2032 use U-2436 8722684*PED December 2031 — 8722684 June 2031 substance, product 11458134*PED December 2027 — 8969355*PED December 2027 — 9227946*PED December 2027 — 9125908*PED December 2027 — 9125909*PED December 2027 — 9125910*PED December 2027 — 9861630*PED December 2027 — 9125910 June 2027 use U-2309 9125909 June 2027 use U-2309 9125908 June 2027 use U-2309 8969355 June 2027 use U-1668 9227946 June 2027 use U-1668 11458134 June 2027 product 9861630 June 2027 use U-1668 7144884*PED December 2026 — 7144884 June 2026 substance, product
Regulatory exclusivity Code Expires PED February 2027 M-232 August 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.